Improvement in Quality of Life and Non‐Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa
European Journal of Neurology · 2026
DOI: 10.1111/ene.70731 ↗At a glance
Multizentrische Studie in European Journal of Neurology, 2026. Written by Diego Santos García and 4 co-authors. Institution: Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain. Major MEDLINE topics: Parkinson Disease, Quality of Life, Levodopa, Antiparkinson Agents. Cited 2 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Esteve Pharmaceuticals.
Abstract (original language)
Background
CVT‐301 (Inbrija) has demonstrated its effectiveness in treating OFF periods in people with Parkinson's disease (PwP). However, its effect on non‐motor symptoms (NMS) and quality of life has not been researched yet. Our aim was to analyze the change observed in health‐related quality of life (HRQoL) and, as a secondary exploratory analysis, NMS associated with OFF episodes in PwP treated with CVT‐301.
Methods
INLEVO‐LIFE PD (an open‐label study of the effect of INhaled LEVOdopa on quality of LIFE and non‐motor symptoms in Parkinson's Disease) is a prospective open‐label study conducted in five centers in Spain. The change from baseline (V0) to the end of the observational period (12 ± 2 weeks) (V12w) in the 39‐item Parkinson's Disease Quality of Life Questionnaire (PDQ‐39) total score was the primary efficacy measure.
Results
Forty PD patients (age 62.3 ± 9.2 years; 55% males) were included between March/2024 and November/2025. At 12 weeks, 34 patients were using CVT‐301 and completed the follow‐up (85%). The PDQ39 total score decreased from 43.6 ± 24.2 at V0 to 31.4 ± 20.6 at V12w ( p < 0.0001). A significant decrease was observed in the mean score of 4 domains of the PDQ39. NMS burden was reduced at v12w from the OFF state to 30, 60, and 90 min after using CVT‐301 ( p < 0.0001). Mean daily OFF time decreased by 1.6 ± 1.9 h ( p < 0.0001). Adverse events related to CVT‐301 were reported in 35% of the patients.
Conclusion
HRQoL and NMS associated with OFF episodes improved in PwP after 12 weeks using CVT‐301.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain.
- Grupo de Investigación en Enfermedad de Parkinson y Otros Trastornos del Movimiento, INIBIC (Instituto de Investigación Biomédica de A Coruña), A Coruña, Spain.
- Hospital San Rafael, A Coruña, Spain.
- Fundación Degen, A Coruña, Spain.
- Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
- Complejo Hospitalario de Cartagena, Murcia, Spain.
ORCID profiles: Diego Santos García, María Cerdán Sánchez, Iria Cabo
Funding
- Esteve Pharmaceuticals
Cite
APA
Santos García, D., Cerdán Sánchez, M., Yáñez Baña, R., Cabo, I., & Cimas Hernando, M. I. (2026). Improvement in Quality of Life and Non‐Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa. European Journal of Neurology. https://doi.org/10.1111/ene.70731
Vancouver
Santos García D, Cerdán Sánchez M, Yáñez Baña R, Cabo I, Cimas Hernando MI. Improvement in Quality of Life and Non‐Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa. European Journal of Neurology. 2026. doi:10.1111/ene.70731
BibTeX
@article{SantosGarca2026,
author = {Santos García, Diego and Cerdán Sánchez, María and Yáñez Baña, Rosa and Cabo, Iria and Cimas Hernando, Maria Icíar},
title = {Improvement in Quality of Life and Non‐Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70731}
}
EUVIMED